{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Navitoclax+Dose+Level+1", "query": { "intervention": "Navitoclax Dose Level 1" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 16, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Navitoclax+Dose+Level+1&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T13:20:42.700Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00888108", "title": "Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "ABT-263", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2009-07", "completion_date": "2012-03", "has_results": false, "last_update_posted_date": "2012-05-22", "last_synced_at": "2026-09-04T13:20:42.700Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Fort Lauderdale, Florida • Baltimore, Maryland", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00888108" }, { "nct_id": "NCT05455294", "title": "Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myeloid Malignancy", "Myelodysplastic Syndromes", "Myelofibrosis", "Acute Myeloid Leukemia", "Myeloproliferative Neoplasm" ], "interventions": [ { "name": "Navitoclax", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jacqueline Garcia, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2022-07-18", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-01-28", "last_synced_at": "2026-09-04T13:20:42.700Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05455294" }, { "nct_id": "NCT05215405", "title": "Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients with Relapsed or Refractory ALL or LL", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Relapsed Childhood ALL", "Relapsed Childhood Lymphoblastic Lymphoma" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Navitoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kathleen Ludwig", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "ALL", "summary": "4 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2025-02-03", "last_synced_at": "2026-09-04T13:20:42.700Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05215405" }, { "nct_id": "NCT04472598", "title": "Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myelofibrosis (MF)" ], "interventions": [ { "name": "Placebo for Navitoclax", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Navitoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 252, "start_date": "2020-09-29", "completion_date": "2025-01-29", "has_results": true, "last_update_posted_date": "2026-03-23", "last_synced_at": "2026-09-04T13:20:42.700Z", "location_count": 35, "location_summary": "Springdale, Arkansas • Fullerton, California • La Jolla, California + 29 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Littleton", "state": "Colorado" }, { "city": "Boca Raton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04472598" }, { "nct_id": "NCT06007911", "title": "Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Adult AML", "Refractory AML" ], "interventions": [ { "name": "Navitoclax Dose Level 1", "type": "DRUG" }, { "name": "Navitoclax Dose Level 0", "type": "DRUG" }, { "name": "Navitoclax Dose Level 2", "type": "DRUG" }, { "name": "Venetoclax Dose Level -1", "type": "DRUG" }, { "name": "Venetoclax Dose Levels 0 to 2", "type": "DRUG" }, { "name": "Cladribine", "type": "DRUG" }, { "name": "Cytarabine (Cladribine Low Dose Cytarabine Backbone)", "type": "DRUG" }, { "name": "Cytarabine (CLAG-M Backbone)", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Granulocyte Colony-Stimulating Factor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2024-08-31", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2024-08-13", "last_synced_at": "2026-09-04T13:20:42.700Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT06007911" }, { "nct_id": "NCT00743028", "title": "Assess the Oral Bioavailability of New ABT-263 Formulations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Lymphomas", "Leukemias" ], "interventions": [ { "name": "ABT-263", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2008-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-10-07", "last_synced_at": "2026-09-04T13:20:42.700Z", "location_count": 5, "location_summary": "Encinitas, California • Santa Monica, California • Bethesda, Maryland + 2 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00743028" }, { "nct_id": "NCT03222609", "title": "A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelofibrosis (MF)" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Navitoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 191, "start_date": "2017-10-31", "completion_date": "2025-01-29", "has_results": true, "last_update_posted_date": "2026-01-20", "last_synced_at": "2026-09-04T13:20:42.700Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Cerritos, California • Duarte, California + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Cerritos", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03222609" }, { "nct_id": "NCT01053520", "title": "Assess the Oral Bioavailability of a New ABT-263 Formulation in Healthy Female Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Female Subjects" ], "interventions": [ { "name": "ABT-263", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "FEMALE", "summary": "18 Years to 55 Years · Female only" }, "enrollment_count": 12, "start_date": "2009-10", "completion_date": "2010-01", "has_results": false, "last_update_posted_date": "2010-11-09", "last_synced_at": "2026-09-04T13:20:42.700Z", "location_count": 1, "location_summary": "Waukegan, Illinois", "locations": [ { "city": "Waukegan", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01053520" }, { "nct_id": "NCT02520778", "title": "Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Lung Non-Squamous Non-Small Cell Carcinoma", "Metastatic Lung Non-Squamous Non-Small Cell Carcinoma", "Stage III Lung Non-Small Cell Cancer AJCC v7", "Stage IIIA Lung Non-Small Cell Cancer AJCC v7", "Stage IIIB Lung Non-Small Cell Cancer AJCC v7", "Stage IV Lung Non-Small Cell Cancer AJCC v7" ], "interventions": [ { "name": "Navitoclax", "type": "DRUG" }, { "name": "Osimertinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2016-08-30", "completion_date": "2023-12-04", "has_results": false, "last_update_posted_date": "2024-08-21", "last_synced_at": "2026-09-04T13:20:42.700Z", "location_count": 18, "location_summary": "Sacramento, California • Aurora, Colorado • Tampa, Florida + 11 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02520778" }, { "nct_id": "NCT04041050", "title": "A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myeloproliferative Neoplasm" ], "interventions": [ { "name": "Navitoclax", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2019-11-08", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-02-14", "last_synced_at": "2026-09-04T13:20:42.700Z", "location_count": 12, "location_summary": "Duarte, California • Fullerton, California • La Jolla, California + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04041050" } ] }